Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria.

MLA

Lombion, Naelle, et al. “Prognostic Value of Interim FDG PET-CT in Patients Older than 60 Years with Diffuse Large B-Cell Lymphoma Treated by PMitCEBO plus Rituximab. Comparison between Deauville 5-Point Scale and International Harmonization Project Criteria.” The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society Of., vol. 65, no. 4, Dec. 2021, pp. 402–09. EBSCOhost, https://doi.org/10.23736/S1824-4785.16.02894-6.

APA

Lombion, N., Robin, P., Tempescul, A., LE Roux, P.-Y., Schick, U., Guillerm, G., Ianotto, J.-C., Berthou, C., Salaün, P.-Y., & Abgral, R. (2021). Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria. The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society Of., 65(4), 402–409. https://doi.org/10.23736/S1824-4785.16.02894-6

Chicago

Lombion, Naelle, Philippe Robin, Adrian Tempescul, Pierre-Yves LE Roux, Ulrike Schick, Gaëlle Guillerm, Jean-Christophe Ianotto, Christian Berthou, Pierre-Yves Salaün, and Ronan Abgral. 2021. “Prognostic Value of Interim FDG PET-CT in Patients Older than 60 Years with Diffuse Large B-Cell Lymphoma Treated by PMitCEBO plus Rituximab. Comparison between Deauville 5-Point Scale and International Harmonization Project Criteria.” The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society Of. 65 (4): 402–9. doi:10.23736/S1824-4785.16.02894-6.